Tuesday - May 6, 2025
Kalamazoo, Michigan, March 30, 2023 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for first quarter of fiscal year 2023 on Monday, May 1, 2023. A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company’s first quarter of fiscal year 2023, which ends on Friday, March 31, 2023.
Stryker will host a webcast at 4:30pm ET on Monday, May 1, 2023, to discuss results for its first quarter fiscal year 2023. The webcast can be accessed at Stryker - Events & Presentations. An archive of the webcast will also be available on the company's website two hours after the live call ends.
About Stryker
Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and hospital outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com.
Contacts
For investor inquiries please contact:
Jason Beach, Vice President, Investor Relations at 269-385-2600 or jason.beach@stryker.com
For media inquiries please contact:
Yin Becker, Vice President, Chief Corporate Affairs Officer at 269-385-2600 or yin.becker@stryker.com
Last Trade: | US$374.40 |
Daily Change: | -6.96 -1.83 |
Daily Volume: | 777,640 |
Market Cap: | US$142.730B |
May 01, 2025 March 04, 2025 March 03, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load